Onassis Holdings Corp. announced its entry into the rejuvenation therapy market with a epigenetic programming technology. Through an exclusive perpetual license agreement with a leading Israeli university, Onassis Holdings will have the right to develop, manufacture, market, distribute, and sell products utilizing this cutting-edge technology worldwide.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.031 USD | 0.00% | 0.00% | -13.41% |
2023 | Onassis Holdings Corp. announced that it expects to receive $75 million in funding | CI |
2023 | Onassis Holdings Enters the Rejuvenation Therapy Race with Innovative Epigenetic Programming | CI |
1st Jan change | Capi. | |
---|---|---|
-13.41% | 39.65L | |
+42.38% | 626.15Cr | |
-15.86% | 449.03Cr | |
+6.36% | 328.56Cr | |
-11.28% | 312.36Cr | |
-3.23% | 249.68Cr | |
+45.24% | 194.05Cr | |
-7.89% | 168.5Cr | |
-0.98% | 163.49Cr | |
-11.32% | 156.41Cr |
- Stock Market
- Equities
- ONSS Stock
- News Onassis Holdings Corp.
- Onassis Holdings Enters the Rejuvenation Therapy Race with Innovative Epigenetic Programming